Catheter Precision announced several updates for their VIVO non-invasive mapping system. Over the last 60 days and through the month of October the company has participated in several industry meetings where VIVO has been or will be highlighted. During the recent European Society of Cardiology meeting congress Professor Tarv Dhanjal from the University of Warwick Hospital in Coventry, UK, presented data of 20 patients from the “Accuracy of a non-invasive mapping system for the localisation of re-entrant VT site of origin and its relationship to myocardial scar on cross-sectional imaging” study. This study currently has 40 patients enrolled and is expected to enroll a total of 50 patients. It is anticipated that this final data to be available in 2025 and that the data will remain positive as enrollment and study conclusion comes to an end. Highlights of the most recent presentation include procedural success in 90% of patients at mean follow up of 7.3 +/- 4.7 months in patients with scar related VT.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision receives Chinese patent for LockeT
- Catheter Precision expands LockeT distribution to Middle East
- Catheter Precision reports first purchase order for LockeT in Pacific Northwest
- Catheter Precision announces presentation at ESC Symposium
- Catheter Precision reports LockeT purchase order in greater Chicago area
